$124.760
-1.909 (-1.53%)收盘时
INBX 资讯
INBX 事件
Company Reports Q2 Revenue of $0, Cash Equivalents at $133.3M
Reports Q2 revenue $0 vs. $1.3M last year. As of June 30, the company had cash and cash equivalents of $133.3M.
Inhibrx Submits Biologics License Application for Ozekibart
Inhibrx Biosciences announced that the U.S. FDA has accepted for filing its Biologics License Application seeking approval of ozekibart for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The FDA has not identified any filing review issues at this time and has assigned a Prescription Drug User Fee Act goal date of April 14, 2027. "The FDA's acceptance of our BLA for ozekibart is a monumental milestone for Inhibrx and, more importantly, for the chondrosarcoma community," said Mark Lappe, CEO of Inhibrx. "Chondrosarcoma is an aggressive and devastating bone cancer and there are currently no approved therapies for patients suffering from this disease. We look forward to working closely with the FDA during this review process to potentially bring this first-in-class targeted therapy to patients as quickly as possible."
Company Cash and Cash Equivalents Rise to $161.7M
As of March 31, 2026, the company had cash and cash equivalents of $161.7M, as compared to $124.2M as of December 31, 2025.
Inhibrx Biosciences Reports Positive Interim Results for INBRX-106 Phase 2
Inhibrx Biosciences announced positive interim results from the randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab - the combination arm - versus pembrolizumab monotherapy - the control arm - in first-line patients with treatment-naive, PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma, or HNSCC. 11 out of 25 patients in the INBRX-106 combination arm achieved a confirmed objective response, compared with 6 out of 28 patients in the control arm. This represents a 22.6% absolute increase in confirmed responses. Three complete responses were observed in the INBRX-106 combination arm. These clinical findings were supported by pharmacodynamic data, which showed up to a 15-fold increase in peripheral CD8+ and CD4+ T-cell proliferation and up to a four-fold increase in activation in INBRX-106 combination-treated patients compared with up to 2.5-fold and 1.5-fold increases, respectively, in those receiving pembrolizumab alone. The combination of INBRX-106 and pembrolizumab was generally manageable, with a safety profile consistent with the addition of an active immunostimulatory agent to checkpoint blockade. The progression-free survival data from the Phase 2 portion of the HexAgon study are expected to become available in Q4. The company plans to begin the Phase 3 portion of the HexAgon study during Q3. In addition, the company is beginning to plan for expansion into the front-line metastatic NSCLC setting, with studies expected to begin in 2027.
U.S. Stocks Rise Broadly on U.S.-Iran Ceasefire News
The major averages finished broadly higher following the announcement that the U.S. will extend its ceasefire with Iran indefinitely. Equities advanced in spite of reports of renewed tensions in the Strait of Hormuz, continued disruptions to shipping and oil prices rising.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Boeingreportedearnings and revenueAT&Treportedand reiterated its FY26 earnings guidanceAlibabaand Tencentare in talks to invest in DeepSeek,Elon Musk's SpaceX said it has thelater this year for $60BPalantirand the USDA signed a $300M2. WALL STREET CALLS:Wells FargoAirbnbto Overweight on "significant business inflection"BofATwilioto Buy from UnderperformBiogento Buy at UBSZscalerto Equal Weight at Morgan StanleyBarclaysPrudentialto a sell-equivalent rating amid "too many headwinds"3. AROUND THE WEB:The U.S. Supreme Court unanimously ruled for Michigan officials, finding that Enbridge Energymissed the deadline to move its pipeline dispute into federal court, NY Times reportsGhana's mining regulator has told Newmontand AngloGoldto shift mining operations over to local contractors or face sanctions, Reuters saysInhibrx Biosciences'INBRX-106 cancer drug is drawing interest from Merckand Japan's Ono Pharmaceuticals, Reuters reportsAfter Bloomberg reported yesterday, citing sources, that Deutsche Telekomis considering a full combination with T-Mobile, CNBC's David Faber said his sources call such speculation "way ahead of itself" and that there is "nothing imminent at all" regarding any type of such dealMicronis pushing U.S. lawmakers to pass the "MATCH Act," which would tighten export restrictions on chipmaking equipment used by Chinese semiconductor firms and close gaps in existing controls, Reuters says4. MOVERS:GE Vernovaincreased afterand raising its guidance for FY26Kopinwas higher after being awarded aRogers Communicationsgained in New York after, backing its guidance for FY26, and declaring a C$0.50 per share quarterly dividendSportsradarfell as short shellers are, though the company calls those claims "factually inaccurate"Calixwas lower afterand providing guidance for FY265. EARNINGS/GUIDANCE:NVR, with EPS and revenue missing consensusStifel, with EPS beating consensusMoodyand reaffirmed its guidance for FY26Masco, with CEO Jon Nudi commenting on "strong first quarter operating results in an extremely dynamic environment"Teledyneand raised its guidance for FY26INDEXES:The Dow rose 340.65, or 0.69%, to 49,490.03, the Nasdaq gained 397.60, or 1.64%, to 24,657.57, and the S&P 500 advanced 73.89, or 1.05%, to 7,137.90.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。